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A Founder Mutation in PET100
Causes Isolated Complex IV Deficiency
in Lebanese Individuals with Leigh Syndrome
Sze Chern Lim,1,2,15 Katherine R. Smith,3,4 David A. Stroud,5 Alison G. Compton,1,2 Elena J. Tucker,1,2
Ayan Dasvarma,1,16 Luke C. Gandolfo,3,6 Justine E. Marum,1,17 Matthew McKenzie,7 Heidi L. Peters,8
David Mowat,9 Peter G. Procopis,10,11 Bridget Wilcken,11 John Christodoulou,11,12,13 Garry K. Brown,14
Michael T. Ryan,5 Melanie Bahlo,3,6 and David R. Thorburn1,2,8,*
Leigh syndrome (LS) is a severe neurodegenerative disorder with characteristic bilateral lesions, typically in the brainstem and basal
ganglia. It usually presents in infancy and is genetically heterogeneous, but most individuals with mitochondrial complex IV (or cyto-
chrome c oxidase) deficiency have mutations in the biogenesis factor SURF1. We studied eight complex IV-deficient LS individuals from
six families of Lebanese origin. They differed from individuals with SURF1mutations in having seizures as a prominent feature. Comple-
mentation analysis suggested they had mutation(s) in the same gene but targeted massively parallel sequencing (MPS) of 1,034 genes
encoding known mitochondrial proteins failed to identify a likely candidate. Linkage and haplotype analyses mapped the location of
the gene to chromosome 19 and targeted MPS of the linkage region identified a homozygous c.3G>C (p.Met1?) mutation in
C19orf79. Abolishing the initiation codon could potentially still allow initiation at a downstream methionine residue but we showed
that this would not result in a functional protein. We confirmed that mutation of this gene was causative by lentiviral-mediated pheno-
typic correction. C19orf79 was recently renamed PET100 and predicted to encode a complex IV biogenesis factor. We showed that it is
located in the mitochondrial inner membrane and forms a ~300 kDa subcomplex with complex IV subunits. Previous proteomic ana-
lyses of mitochondria had overlooked PET100 because its small size was below the cutoff for annotating bona fide proteins. The muta-
tion was estimated to have arisen at least 520 years ago, explaining how the families could have different religions and different
geographic origins within Lebanon.Introduction
Leigh syndrome (LS [MIM 256000] or subacute necro-
tizing encephalomyelopathy) is a severe, progressive
neurodegenerative disorder characterized by bilateral
lesions in the brainstem, basal ganglia, thalamus, and spi-
nal cord.1–3 Most often it presents in infancy with devel-
opmental delay, seizures, dysarthria, and ataxia, as well
as episodes of lactic acidosis. It is caused by severe defi-
ciency of ATP production in the mitochondria4 resulting
from defects affecting mitochondrial oxidative phosphor-
ylation (OXPHOS) or pyruvate metabolism.5 It is geneti-
cally heterogeneous, with mutations in almost 50 genes
able to cause LS.5,6 The genes identified so far encode com-
ponents or factors required for assembly and function of
OXPHOS complexes I, II, IV, and V or maintenance
or expression of mitochondrial DNA (mtDNA) or the
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Cytochrome c oxidase (COX) or OXPHOS complex IV
(CIV) deficiency is one of the major causes of LS, although
it can also cause a range of other clinical presentations.
Functional CIV comprises a homodimer of 14 subunits,
which is assembled via a multistep process. In addition
to subunits, there are also four redox-active components
(two copper centers and two heme a moieties) and three
redox-inactive metal ions with unknown function (zinc,
magnesium, and sodium ions).9,10 Studies done on yeast
mutants with respiratory defects have identified more
than 20 biogenesis factors required for CIV assembly.11–13
Not all of those yeast proteins have obvious human homo-
logs.14 Identification of human CIV biogenesis factors has
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followed by bioinformatic or functional studies impli-
cating the encoded protein in CIV biogenesis.
Mutations causing isolated CIV deficiency have been
identified in four nuclear DNA (nDNA) and three mtDNA-
encoded CIV subunits, as well as 11 other nDNA-encoded
biogenesis factors that are required for the transcription,
translation, and assembly of CIV holoenzyme.5,6,15–18 Of
those genes, mutations in NDUFA4, which was recently
shown to encode the 14th CIV subunit,19 SURF1 (MIM
185620), COX10 (MIM 602125), COX15 (MIM 603646),
LRPPRC (MIM 607544), and TACO1 (MIM 612958) cause
LS.2,3,15,20–24 SURF1mutations are themost common cause
of CIV deficiency,2,3 although themajority of CIV-deficient
individuals do not yet have a molecular diagnosis. Individ-
uals with SURF1mutations usually present in infancy with
typical LS symptoms anddie before 10 years of age.25 SURF1
facilitates the early stages of CIV assembly,26 where its
bacterial homologs were shown to mediate the assembly
of heme moieties into COX1.27,28
Of the other CIV biogenesis factors, C2orf64 (recently
renamed COA5) also has a role in an early stage of CIV
assembly.17 COX10 and COX15 are involved in the
mitochondrial heme a biosynthesis whereas SCO1 and
SCO2 are required for the biogenesis of the CuA site of
COX2.29 LRPPRC,TACO1, andC12orf62 (recently renamed
COX14) regulate the transcription and translation of CIV
subunits.18,21,30,31 ETHE1 is involved in the catabolism of
sulfide and its mutation leads to isolated CIV deficiency in
muscle and brain.32 The role of FASTKD2 in CIV biogenesis
is not clear but itsmutationcauses isolatedCIVdeficiency.33
In this study, we identify PET100 as a CIV biogenesis
factor in humans and characterize its location and role in
mitochondria.We found PET100 (MIM 614770)mutations
in ten Lebanese individuals with LS and isolated CIV defi-
ciency. All affected individuals were homozygous for a
founder mutation, which we estimate arose at least 520
years ago.Subjects and Methods
The studies were approved by the human research ethics commit-
tee at the Royal Children’s Hospital, Melbourne. All samples and
pedigrees were obtained as part of diagnostic investigations, and
families provided informed consent.Clinical Information
Individual A1 (family A, II-2 in Figure 1A) presented at 4months of
age with continuous crying and was encephalitic on admission to
the emergency department. His development had been slow in all
areas. A CTscan at that time showed bilateral symmetrical involve-
ment of the putamen and thalamus. MRI scan at 5 months
confirmed those findings and identified a lactate doublet on
MRS. An MRI at 6 months showed marked progression of the dis-
ease with involvement of basal ganglia including the caudate and
globus pallidus. There were also frontotemporal white matter
changes. His blood lactate was elevated, ranging from 4.5 to
9.5 mmol/l (normal range [NR] < 2.5 mmol/l) and cerebrospinal210 The American Journal of Human Genetics 94, 209–222, Februaryfluid (CSF) lactate was raised to 6.2 mmol/l (NR < 2.5 mmol/l).
From about 5 months he started having seizures, and toward the
end was having 3–7 seizures/day, not responding to vigabatrin.
He was also on nasogastric feeds from about 5 months and did
not obviously fix and follow. He died at 8 months of age and in
the last weeks he had breathing dysregularity with apneic epi-
sodes. He died at home, presumably of a prolonged apnea.
The parents of individual B1 (family B, II-7 in Figure 1A) came
from Tripoli in Northern Lebanon. The first four children in the
family were born in the 1970s in Lebanon and died within the first
year of life without clear diagnoses but all had developmental
delay and seizures. B1 was born at term after an uneventful preg-
nancy. He was irritable and inconsolable from about 6 weeks of
age with developmental delay thought to be present from birth.
At 2 months he was noted to have central hypotonia with periph-
eral hypertonia. He had seizures commencing at 6 months of age,
which progressed to status epilepticus over the course of a few
days. He reacted to loud sounds but there was generally a paucity
of movement. The seizures settled with anticonvulsants but he
continued to show gross developmental delay and failure to
thrive. Cranial CT scan at 2 months was regarded as probably
normal but repeat CT scan at 6 months showed extensive symmet-
rical low density white matter lesions with mild ventricular
enlargement plus low density lesions in the heads of the caudate
nuclei consistent with LS. Blood lactate was elevated to
7.0 mmol/l and CSF lactate levels were 3.3 and 4.0 mmol/l on
two occasions. He died at home at 8 months of age.
The parents of individual C1 (family C, II-4 in Figure 1A) were
from nearby villages in northern Lebanon. There was no history
of metabolic disease in the family, although C1’s older brother
was suggested to have Rolandic seizures. C1 was born with good
Apgar scores after a normal delivery. She presented at 3 months
of age with episodes of stiffening and pallor. She was diagnosed
as having reflux and responded well to cisapride. She had normal
development when she was first seen in the clinic. At 4 months of
age, she developed episodes of arm and leg extension with cir-
cumoral cyanosis. On examination, she was awake and active,
but she did not fix or follow and had extremely poor head control.
Head ultrasound showed bilateral subdural collections, which was
confirmed by CT scan. Her later MRI result was consistent with LS.
She had bilateral lamellar cataracts and screens for possible causes
were performed but results were negative. She had low serum bi-
carbonate (14mmol/l on arrival, NR> 19mmol/l), elevated serum
and CSF lactate levels (5.4 and 4.8 mmol/l, respectively), and
elevated serum and CSF pyruvate levels (0.19 and 0.13 mmol/l,
respectively, NR < 0.1 mmol/l). She is currently 15.5 years of age
and in a near-vegetative state. She is fed by gastrostomy and has
epilepsy, for which she receives multiple anticonvulsants, and
marked thoracic scoliosis with reduced lung volume on the left
with frequent respiratory infections.
Individual D1 (family D, II-3 in Figure 1A) had normal birth
weight but was an irritable baby with poor head control and was
slow to fix and follow. At 6 months of age, he had acute onset of
dystonic posturing and probable generalized seizure activity. He
showed good physical growth and no dysmorphic features but
had marked hypotonia with minimal spontaneous activity. His
plasma and CSF lactate levels were raised to 3.0 and 4.1 mmol/l,
respectively. Cranial MRI showed symmetrical high-intensity sig-
nals in the putamen, thalamus, and medulla. At 10 years of age,
he had profound mental retardation, microcephaly, spastic quad-
riplegia, short stature, and seizures. Now at the age of 24, he is in a
chronic vegetative state with spastic quadriplegia and only very6, 2014
Figure 1. Ten PET100 Individuals from Eight Families of Lebanese Ancestry
(A) Pedigrees of the eight Lebanese families. Double horizontal line indicates consanguinity. Squares and circles represent males and
females, respectively. Diamonds indicate gender is unknown. Black symbols represent affected individuals and diagonal lines denote
deceased individuals. Grey symbols represent children who died without investigation and remain undiagnosed.
(B) A map of Lebanon with red pins marking the regions of origin of the parents in families B, C, D, E, G, and H. Scale bar represents
20 km.
(C) Summary of the complementation analysis based on galactose sensitivity of fused cell lines. ‘‘A1–F1’’ and ‘‘SURF1’’ indicate fibroblast
cell lines from the Lebanese LS and SURF1 individuals, respectively. 143B r cell line does not contain mtDNA. Yand X indicate positive
and negative complementation in galactose media, respectively.primitive communication abilities. He is fed via a gastrostomy
tube. From the same family, individual D2 (family D, II-1 in
Figure 1A) had seizures and delay inmotormilestones at 4 months
of age. On investigation at 5 months, his EEG showed right-sided
focal patterns, and CT showed cerebral atrophy. Urine organic and
amino acids at the time were normal. At 7 months old, he was
readmitted to the hospital in status epilepticus and required venti-
lation. His lactate level was normal in the blood (1.2 mmol/l) but
was raised to 3.8 mmol/l in the CSF. He died after elective extuba-
tion, with neuropathological findings of LS plus cerebral atrophy
and recent myocardial infarction.
Individual E1 (family E, II-1 in Figure 1A) presented at 4 months
of age with profound global developmental delay, hypotonia, and
seizures. At 7 months of age, he had divergent strabismus and was
unable to fix and follow. His cranial CT scan at 8 months was un-
remarkable. At 7 years, he had spastic quadraparesis and his height
and weight were on the third centile. He developed kyphoscoliosis
and dementia prior to his death at 16 years of age. From the same
family, individual E2 (family E, II-3 in Figure 1A) had develop-The Americmental delay, hypotonia, and a divergent squint at 9 months
of age. Subsequently, he had failure to thrive and developed
myoclonic/tonic seizures and vertical and horizontal nystagmus.
His blood lactate levels were elevated to 4.3 and 5.4 mmol/l on
two occasions. Epileptic discharges were shown by EEG. Cranial
CT scan at 1 year of age showed cerebral atrophy with bilateral hy-
perlucent areas deep to the Sylvian fissures compatible with LS.
Individual F1 (family F, II-2 in Figure 1A) was born at full term
after a normal delivery. He had been noted to be somewhat hyper-
tonic and there were concerns regarding his visual attention. He
was referred to the metabolic unit at 6 months of age when he
was admitted with a history of viral meningitis. At that time, he
had persistent elevated lactate in the blood (5–11 mmol/l) and
CSF (5.8 mmol/l) and an abnormal CT scan with bilateral low
attenuation signals in both lentiform nuclei. He was not dysmor-
phic and hadmottled skin. His height and weight were on the 25th
percentile and his head circumference was on the 3rd percentile.
He was hypotonic with roving eye movements and no visual fixa-
tion. He later had seizures (commenced before 8 months old) withan Journal of Human Genetics 94, 209–222, February 6, 2014 211
an infantile spasm pattern. At the age of 9 years his height, weight,
and head circumference are all below the 3rd percentile. Seizures
have become gelastic and generalized in nature. He has spastic
quadraparesis, a bulbar palsy, and easy obtainable clonus and ab-
sent reflexes suggesting development of a peripheral neuropathy.
He has a severe hearing deficit and visual impairment. There
have been a number of hospital admissions for recurrent chest
infections.
Individual G1 (family G, II-2 in Figure 1A) presented with devel-
opmental delay and hypotonia at 4 months of age after an un-
eventful prenatal/neonatal course. Her seizures were treated with
nitrazepam and vigabatrin. Her head circumference was on the
90th centile, and her weight and length were on the 50th–75th cen-
tile. She was extremely hypotonic with significant head lag. She
did not fix or follow or respond to visual confrontation. Her
reflexes were brisk but equal in both upper and lower limbs. She
frequently had myoclonic jerks. She had elevated lactic acid and
alanine levels in the urine. Lactate level in her serum was mildly
elevated (2.85 mmol/l). Her CSF lactate level was elevated to
5.6 mmol/l. Pyruvate level was within the normal range in blood
(0.09 mmol/l) but was elevated in CSF (0.18 mmol/l). CT scan
showed cortical atrophy and EEG showed abnormal spike and
wave andnonclassic hypsarrhythmia.G1 died at 12months of age.
The parents of individual H1 (family H, II-4 in Figure 1A) origi-
nated from two villages in northern Lebanon, which are about
half an hour drive apart. H1 was born at 38 weeks with birth
weight of 2.98 kg. He had hypoglycemia in the newborn period
and required 4 days in the special care nursery. He presented at
4 months with marked irritability and a preceding history of
motor delay. His blood and CSF lactate levels were elevated (6.3–
11.1 mmol/l and 4.19 mmol/l, respectively). His blood pyruvate
level was also elevated (0.17 and 0.3 mmol/l on two occasions).
Urine organic acid analysis showed marked ketosis with elevated
lactate and alanine. He had a twin sister whowas not affected. Cra-
nial MRI showed high-intensity signals in the putamen. He went
on to have very poor neurological development with myoclonic
spasms (treated with clobazam), cortical blindness, and feeding
difficulties. He had a Nissen fundoplication and insertion of gas-
trostomy at 17 months, but his condition continued to progress
and he died at 3.5 years of age.Biochemical and Complementation Analyses
Spectrophotometric enzyme assays assessing mitochondrial
OXPHOSactivity in cultured fibroblasts and skeletalmuscle or liver
biopsieswere performed as describedpreviously.34 Pairs of cell lines
were cocultured (53 104 cells of each cell line) in Dulbecco’s modi-
fied eaglemediumuntil confluent in a25 cm2flask.Cellswere fused
by exposure to 1.5ml Polyethylene glycol 1500 (Roche) for 70 s. 13
104 cells of each fused cell line were plated in each 0.75 cm2 well
and allowed to recover overnight in glucose medium (serum-free
medium supplemented with 5 mM glucose, 10% dialyzed FBS,
and 1% PBS) before selective medium (serum-free medium lacking
glucose and supplementedwith 5mMgalactose, 10%dialyzed FBS,
1% PBS, and 5 mM sodium azide) was applied. Cell survival beyond
7 days inferred positive complementation.Linkage and Haplotype Analysis
Genome-wide SNP genotyping of DNA extracted from fibroblasts
of six affected individuals (A1, B1, C1, D1, E2, and F1) was
performed with the Illumina Human1M-Duo BeadChips at the
Australian Genome Research Facility (AGRF), Melbourne. We212 The American Journal of Human Genetics 94, 209–222, Februaryanalyzed genotypes for a subset of 12,156 SNPs that were chosen
to have high heterozygosity and lie in approximate linkage
equilibrium.35 Inbreeding coefficients (F) were estimated with
FEstim.36,37 Based on these results (Table S1 available online), hy-
pothetical first cousin once removed inbreeding loops were added
to pedigrees C and E; reported inbreeding loops were retained
for the other pedigrees. Multipoint parametric linkage analysis
under a fully penetrant recessive genetic model and accounting
for consanguinity was performed with MERLIN.38 Haplotypes
inferred to be ‘‘most likely’’ by MERLIN were plotted with
HaploPainter.39
Sanger Sequencing
Sanger sequencing of candidate genes was performed with BigDye
Terminators v3.1 Cycle Sequencing kit (Applied Biosystems) as per
manufacturer’s protocol. Details of primers and conditions are
available on request. DNA sequences from affected individuals
were compared against the RefSeq sequence and/or the sequence
of a healthy control that was sequenced in parallel. Variants pre-
sent in the healthy control, or in dbSNP or ethnically matched
controls with allele frequency ofR0.005, or not predicted to cause
a splicing defect40,41 were regarded as probably benign.
MitoExome Sequencing
The entire mtDNA and all exons of 1,381 nuclear genes in B1, C1,
D1, and E2 were targeted for massively parallel sequencing (MPS).
Subsequent analyses were restricted to the mtDNA and 1,034 nu-
clear genes with strong evidence of mitochondrial association.42
Methods for target selection, massively parallel sequencing, align-
ment and variant detection, and prioritization were described
previously.42
Targeted MPS
The target region (chr19: 6,952,512–9,811,452) was captured with
the Agilent SureSelect Target Enrichment system via 120 bp baits
with 23 tiling frequency. DNA samples were prepared from fibro-
blasts of affected individuals and submitted to the AGRF, Mel-
bourne, for capture and sequencing. Samples were indexed and
sequenced in a single lane on the Illumina HiSeq 2000 platform
with 100 bp single-end reads.
Reads were aligned to the UCSC Genome Browser hg19
reference genome via Novoalign (v. 2.07.09), with quality score
calibration performed. Multi-mapping reads were removed;
potential PCR duplicates were removed with Picard 1.47. Depth
of coverage was calculated with the Genome Analysis Toolkit
(GATK) (v. 1.0.5974).43,44
Variants were detected and genotyped with the mpileup
and bcftools view utilities from SAMtools (v. 0.1.18),45,46 with
low-confidence variants discarded by the vcfutils.pl script from
the same package with default settings. Variants were anno-
tated against UCSC KnownGene annotation,47 dbSNP 132,48
and 1000 Genomes (Nov 2010 and May 2011 releases)49 by
ANNOVAR.50 Sequence variants of interest were verified with
restriction fragment length polymorphism (RFLP) analysis and/
or Sanger sequencing.
RFLP Analysis
PCR product amplified by forward primer 50-gccagacccgttttctattg-
30 and reverse primer 50-aacccactcctgtgtccact-30 was digested for
5 hr with MboI (Promega) as per manufacturer’s protocol and
resolved on 2% agarose gels.6, 2014
Sequenom Genotyping Assay
A specifically designed multiplexed MALDI-TOF mass spec-
trometry (Sequenom) assay was used to genotype 81 unrelated
Lebanese individuals for the c.3G>C PET100 mutation. These
individuals largely comprised subjects referred for investigation
of possible OXPHOS enzyme defects. Genotypes were called by
the MassARRAY System Typer v. 4.0 software (Sequenom). Details
of primers and conditions are available on request.
Evolutionary Conservation
Human PET100 (RefSeq accession number NP_001164626.1) was
aligned with its orthologs in seven additional species: P. abelii
(XP_002828599.1), M. mulatta (XP_001097045.1), B. taurus
(XP_002688903.1), C. familiaris (XP_854300.2), M. musculus
(NP_001182173.1), R. norvegicus (NP_001182174.1), and D. rerio
(XP_003198224.1) via ClustalW2 softwarewith default parameters.
Estimation of Mutation Age
Existing methods for estimating the age of a mutation51,52 depend
on large sample sizes or knowing the population frequency of the
mutation. We have developed a method53,54 based on the length
of mutation-harboring ancestral segments by using ideas devel-
oped by McPeek and Strahs55 in the context of fine mapping
with linkage disequilibrium.
Assuming the Haldane recombination model, it can be shown
that the length (in Morgans) of an ancestral segment after t gener-
ations has a gamma(2,t) distribution. By using a sample of segment
lengths, we derived amaximum likelihood estimate of the t param-
eter, then modified the estimate to become unbiased. The lengths
wereassumedtobe statistically independent,whichwasequivalent
to assuming that the sampled segments had independent recombi-
nation histories, a plausible assumption in fast-growing popula-
tions. Exact confidence intervals were obtained by deriving the
sampling distribution of a pivotal quantity involving the estimate
and the true mutation age by using properties of the gamma distri-
bution.The largewidthof the reported intervalwasdue to the small
sample size. A generation time of 20 years was assumed to convert
from age in generations to age in years.
The sample of ancestral segment lengths was obtained from the
Illumina Human1M-Duo BeadChips SNP genotype data of A1,
B1, C1, D1, E2, and F1. The lengths were defined by regions where
there was continuous haplotype sharing between at least two indi-
viduals around the mutation, for the reason that such sharing (of
hundreds of consecutive markers) could be plausibly explained
only by assuming that the regions were identical by descent, i.e.,
they were ancestral segments. Since the sampled individuals had
a recessive disease, as a result of consanguinity, each had a large re-
gionofhomozygosity surrounding themutation, and this removed
the need to phase the SNP data: for obtaining the lengths, contin-
uous haplotype sharing is equivalent to continuous sharing of
identical homozygous genotypes. The ancestral segment lengths
obtained were 3.06, 3.84, 4.65, 2.63, 3.51, and 3.84 cM.
Lentiviral Transduction
The open reading frame of PET100 alone or fused to a 30 FLAG-tag
was cloned into the 4-hydroxytamoxifen-inducible lentiviral
vector, pF_5x_UAS_MCS_SV40_puroGEV16-W.56 PET100 viral
particles were generated and cultured fibroblasts were transduced
as described previously.57 Three independent transductions were
performed and cells were harvested after 8–10 days selection
with 1 mg/ml puromycin.The AmericImmunofluorescence
D2 fibroblasts were transiently transfected with pcDNA3 (Invitro-
gen) containing PET100 fused with a 30 FLAG-tag (PET100FLAG).
Mitochondria were stained withMitoTracker Red, after which cells
were fixed in 4% (w/v) paraformaldehyde and analyzed by immu-
nostaining with the FLAG M2 antibody (Sigma). Nuclei were
labeled with Hoechst dye.
In Vitro Protein Import into Isolated Mitochondria
Mitochondriawere isolated fromHEK293Tcells and cultured fibro-
blasts as described previously.58 For in vitro transcription, PET100
and PET100D1-9 were amplified from cDNA with forward primers
incorporating a SP6 promoter as described by Stojanovski et al.59
PCR products were transcribed with the mMessage mMachine
SP6 kit (Ambion) according to manufacturer’s instructions, and
transcripts were translated in rabbit reticulocyte lysate (Promega)
in the presence of [35S]methionine/cysteine protein labeling
mix (Perkin Elmer Life Sciences).59 Radiolabeled proteins were
incubated with isolated mitochondria at 37C for various times as
indicated. Trypsin treatment, dissipationofDJm, swelling, andcar-
bonate extraction were performed according to Stojanovski et al.59
SDS-PAGE and Blue Native Gel Electrophoresis
Protein lysates were prepared from cultured fibroblasts as
described previously.42 10 mg of each protein lysate was analyzed
by SDS-PAGE as described previously.42 Isolated mitochondria
(25–50 mg) were separated on 10%–16% polyacrylamide Tris-tri-
cine gradient gels as described previously.60 BN-PAGE was per-
formed as described previously.60 Membrane protein complexes
(solubilized in 1% digitonin) were separated on a 4%–13% acryl-
amide-bisacrylamide BN-PAGE gel.
Immunoblotting
Primary antibodies used were against COX1, COX2 and SDHA
(MitoSciences), NDUFA9, TOM70 and mt-HSP70 (rabbit poly-
clonal), TIM23 (BD Biosciences), and VDAC1 (Calbiochem).
Where statistical significance was provided for the differences in
protein levels, quantification of immunoblots was performed by
densitometry measurement by ImageJ software followed by a
two-way repeated-measures analysis of variance (ANOVA) for com-
parisons of groups and a post hoc analysis by the Bonferroni
method to determine statistically significant differences.
Radiolabeling of mtDNA-Encoded Translation
Products
Radiolabeling of mtDNA-encoded subunits was performed as pre-
viously described.61 In brief, cells were pretreated with 50 mg/ml
chloramphenicol (Sigma) in Dulbecco’s modified eagle medium
(DMEM, Invitrogen) containing 10% (v/v) FBS for 12 hr before
labeling. To inhibit cytosolic translation, cells were subsequently
incubated with 0.1 mg/ml cycloheximide (Sigma) for 15 min
at 37C in methionine-free DMEM (Invitrogen) containing 5%
(v/v) dialyzed FBS (Thermo Scientific). The pulse was performed
by addition of 20 mCi [35S]methionine/cysteine (EXPRE35S35S Pro-
tein Labeling Mix, PerkinElmer Life Sciences) for 2 hr, followed by
the addition of 0.1 mM unlabeled methionine for 15 min. For the
chase, media was removed and replaced with DMEM containing
10% (v/v) FBS and cells were cultured at 37C for the times indi-
cated. Mitochondria were isolated as described above and mem-
brane protein complexes were solubilized in 1% Triton X-100
and separated on 4%–13% acrylamide-bisacrylamide BN-PAGEan Journal of Human Genetics 94, 209–222, February 6, 2014 213
Table 1. Clinical and Biochemical Characteristics of Individuals with PET100 Mutation
Subject ID Sex Age of Onset
Age of Death
(Current Age)
Clinical
Presentation % CIV Activitya
Relationship
between Parents
Religious Background
of Parents
A1 M 4 months 0.7 years LS 17 (F), 19 (M), 22 (L) first cousins Christian
B1 M 1.5 months 0.7 years DD, FTT, seizures 24 (F) second cousins Sunni Muslim
C1 F 3 months (15.5 years) LS 10 (F), 21 (M) unrelated, from
nearby villages
Maronite Catholic
D1 M 6 months (24 years) LS, dystonia, seizures 27 (F) first cousins Maronite Catholic
D2 M 4 months 0.6 years LS, seizures 22 (F)
E1 M 4 months 16 years DD, FTT, seizures 29 (F) unrelated Maronite Catholic
E2 M 9 months (27 years) LS, seizures 25 (F)
F1 M 6 months (9.7 years) LS, seizures 34 (F) first cousins Muslim
G1 F 4 months 1 year DD, seizures 12 (F), 39 (L) first cousins once
removed
Christian Orthodox
H1 M 4 months 3.5 years LS, seizures 51 (F), 48 (M), 21 (L) second cousins Maronite Catholic
Abbreviations are as follows: LS, Leigh syndrome; DD, developmental delay; FTT, failure to thrive.
aCIV activity is expressed as percent of control mean value for CIV activity relative to citrate synthase activity in fibroblasts (F), skeletal muscle (M), or liver (L).gels. For 2D-PAGE, gel slices were excised and subsequently sepa-
rated on 10%–16% polyacrylamide Tris-tricine gradient gels as
described previously.61Results
Eight Lebanese Individuals with Isolated CIV
Deficiency Had a Unique Form of LS and Belong to a
Single Complementation Group
We studied eight Australian individuals of Lebanese
ancestry with LS or Leigh-like encephalopathy and CIV
deficiency (Table 1 and Figure 1A). Residual activity of
CIV was similar to that of typical individuals with SURF1
mutations in skin fibroblasts and skeletal muscle (median
values of 18% to 25%; for details see Table S2). Activities
of OXPHOS complexes I and II in the eight Lebanese indi-
viduals and SURF1 individuals were comparable to normal
controls, whereas complex III activity was comparable to
normal controls in the eight Lebanese individuals and
borderline low in SURF1 individuals (Table S2). The
affected Lebanese individuals thus resembled SURF1 indi-
viduals in having an isolated systemic CIV defect but
they differed from most SURF1 individuals in having
global developmental delay, seizures, and an earlier age
of onset (see Clinical Summaries and Table S3). They
were from six families not known to be related (A–F).
They had a range of religious backgrounds and geographic
origins within Lebanon (Figure 1B). Four of the six families
were known to be consanguineous.
Cells cultured in galactose media are forced to produce
energy via OXPHOS,62 and those with severe OXPHOS
defects die within 7 days. We performed pair-wise cell fu-
sions between the cell lines of the Lebanese individuals
and none survived beyond 7 days in galactose media
(Figure 1C). In contrast, fusion with cell lines containing214 The American Journal of Human Genetics 94, 209–222, Februarya SURF1 defect or lacking mtDNA (r0) resulted in positive
complementation (Figure 1C). The Lebanese individuals
thus belonged to a single complementation group, sug-
gesting a common defective gene.
Linkage and Haplotype Analyses Identified a
Candidate Region on Chromosome 19
We genotyped one affected individual from each family
via Illumina Human1M-Duo arrays. Estimated inbreeding
coefficients revealed undocumented inbreeding in families
C and E, and families B and F were more consanguineous
than reported (Table S1). Although families C and E were
not known to be consanguineous, the parents within
each of the families originated from the same geographical
area.
We performed parametric linkage analysis simulta-
neously for six affected individuals via a fully penetrant
recessive genetic model. A unique linkage peak at chr19:
7,251,842–8,468,337 (UCSC Genome Browser build
hg19) was identified, with a maximum heterogeneity
LOD score of 7.53 (Figure S1). All families showed linkage
to this region (Figure 2A). All six affected individuals were
homozygous within this region and shared identical
homozygous genotypes for a smaller region (chr19:
7,251,842–7,813,268) (Figure 2B), suggesting they might
share amutation inherited from a common ancestor. There
were 49 genes within the broader linkage region, 22 of
which were within the smaller linkage region.
Targeted MPS of Candidate Region Identified a
Mutation in C19orf79
Prior to performing linkage analysis, we Sanger sequenced
SURF1, SCO2 (MIM 604272), TACO1, and 12 nDNA-en-
coded CIV subunit genes. We also sequenced 11 candidate
genes with known or predicted mitochondrial association6, 2014
Figure 2. Linkage and Haplotype
Anlayses of Affected Individuals from
Families A–F
(A) The contribution of each family to the
combined hLOD score peak on chromo-
some 19. LOD scores of individual families
were plotted in black, red, green, blue,
orange, and dark aqua, respectively. The
combined hLOD score was plotted in
purple.
(B) Haplotypes for each affected individ-
uals in the region under the chromosome
19 linkage peak. ‘‘1’’ and ‘‘2’’ are arbitrary
labels to indicate the two different alleles
of each SNP. Different colors indicate
alleles inherited from different ancestors.
Some markers used for linkage analysis
are not displayed for conciseness. All
affected individuals were homozygous by
state from 23.14 to 26.89 cM (red box)
and shared identical homozygous alleles
from 23.14 to 25.05 cM (shaded in gray).from chr19 in at least three of the eight affected individuals
(Table S4). Furthermore, the entire mtDNA and 1,034
nuclear genes encoding the known ‘‘MitoExome’’ were
analyzed for four affected individuals by MPS.42 No puta-
tive pathogenic variant was identified.
Targeted MPS of the candidate region was performed for
one affected individual from each family. The median per-
centage of targeted bases covered by at least two reads was
92% across the six individuals (Table S5). A total of 542 var-
iants were detected within the chr19: 7,251,842–7,813,268
region of shared homozygosity, of which 407 remained
after the removal of low-confidence variants. Of these var-
iants, 95 were rare (absent from the 1000 Genomes data set
or present with <0.01 alternate allele frequency); of these,
three variants were predicted to alter splicing or protein
sequence (Table S6). All six cases were homozygous for
the alternate allele for only one of these three variants:
c.3G>C in PET100 (RefSeq NM_001171155.1). The
mutation segregated with disease in all families and
was predicted to abolish the translation initiation codon
(p.Met1?; Figure S2). It was absent from public data-
bases48,49 but was homozygous in 2/81 ethnically matched
individuals screened. The 81 ‘‘controls’’ were derived from
individuals of Lebanese ancestry who had mostly been
referred for analysis of a suspected OXPHOS defect. OfThe American Journal of Human Gethese, three individuals had isolated
CIV deficiency and were without a
previous molecular diagnosis. Two
of the three (G1 and H1, Figure 1A)
were homozygous for the c.3G>C
mutation and segregation of the mu-
tation with disease was confirmed in
both additional families (Figure S2).
The third individual lacked the
c.3G>C mutation. In addition, we
sequenced the PET100 coding regionin three non-Lebanese individuals with CIV deficiency
and without previous molecular diagnosis. No pathogenic
mutation was identified.
The c.3G>C Mutation in PET100Was Estimated to Be
at Least 520 Years Old
The age of the c.3G>C PET100mutation was estimated (to
the nearest generation) as 43 generations (95% confidence
interval of 26, 83). Assuming an average generation time of
20 years, the mutation was estimated to be 860 years old
(95% confidence interval of (520, 1,660) years).
PET100 Is Localized to the Mitochondrial Inner
Membrane
PET100 encodes a 73 amino acid protein, which was
not known or predicted to have mitochondrial associa-
tion42,64–66 until it was recently identified as the human
ortholog of yeast Pet100p,67 a CIV biogenesis factor in
the mitochondrial inner membrane.68 Szklarczyk and col-
leagues recently demonstrated that reanalysis of raw mass
spectrometry data of isolated mouse heart mitochondria66
identified PET100 peptides, indicative of mitochon-
drial association.67 Our immunofluorescence analysis of
FLAG-tagged human PET100 (PET100FLAG) also revealed
mitochondrial localization (Figure 3A). To investigatenetics 94, 209–222, February 6, 2014 215
Figure 3. Mitochondrial Localization and Assembly of PET100
(A) D2 fibroblasts expressing PET100FLAG were stained with MitoTracker Red (red), fixed, and immunostained for the FLAG epitope
(green). Nuclei were labeled with Hoechst (blue). Colocalization of the expressed PET100FLAG in the mitochondria (yellow) is shown
in the merged image.
(B) Top: The presence of membrane potential (DJm) was required for the import of
35S-labeled PET100 into isolated HEK293Tmitochon-
dria, protecting it from digestion by externally added trypsin. Untreated input lysate is shown for comparison. 10% of input lysate used
in the import was loaded in lane 1. Bottom: [35S]PET100 imported into HEK293T mitochondria was digested by trypsin only after
hypo-osmotic mitochondrial swelling (left) and remained in the membrane (Pellet) fraction after alkaline extraction (Na2CO3) (right).
Abbreviations are as follows: SN, supernatant; WB, immunoblotting.
(C) BN-PAGE (top) or SDS-PAGE (bottom) followed by phosphorimaging showed that [35S]PET100D1-9 was incapable of assembly into the
~300 kDa complex (lanes 4–6) and was not imported into mitochondria (lanes 13–15). Abbreviations are as follows: CI, complex I; CIII,
complex III; CIV, complex IV.
(D) Sequence alignment of human PET100 with its homologs in seven additional vertebrate species. The PET100 in the Lebanese LS
individuals (if present) was predicted to lack the first nine amino acid residues, which are highly conserved in vertebrate species. Asterisk
(*), colon (:), and period (.) indicate that the amino acids are identical, strongly similar, and weakly similar, respectively, across the
aligned species. The transmembrane domain predicted from the human protein67 is boxed.the submitochondrial localization, we used in vitro im-
ported [35S]PET100. The protein is shown to associate
with mitochondria (Figure 3B, lanes 2–4), and after treat-
ment with trypsin, a portion was in a protease protected
location (Figure 3B, lanes 5 and 6). Furthermore, this
accumulation was dependent on the mitochondrial mem-
brane potential for its accumulation inside mitochondria
(Figure 3B, lanes 4 and 7), typical of proteins located
in the mitochondrial inner membrane or matrix.69,70
PET100 lacks a cleavable N-terminal presequence because
the imported protein has the same size as the translated
form (Figure 3B, lanes 1–4). Imported [35S]PET100 was216 The American Journal of Human Genetics 94, 209–222, Februarydigested with trypsin only after mitochondrial swelling,
like TIM23, which is exposed to the intermembrane space
(Figure 3B, lanes 8–10). The control outer membrane
protein, TOM70, was susceptible to trypsin digestion,
whereas matrix-located NDUFA9 was protected as ex-
pected. PET100 contains a predicted transmembrane an-
chor67 (Figure 3D) and remained predominantly in the
membrane fraction after alkaline extraction (Figure 3B),
unlike the peripherally associated mtHSP70. These obser-
vations lead to the conclusion that PET100 is located in
the mitochondrial inner membrane and exposed to the
intermembrane space.6, 2014
Figure 4. The Import of 35S-Labeled
PET100 or Overexpression of PET100
cDNA in Fibroblasts from Affected Indi-
viduals
(A) Samples treated with trypsin and
analyzed by BN-PAGE (top) or SDS-PAGE
(bottom) and phosphorimaging showed
that [35S]PET100 was imported (lanes 13–
22) and assembled (lanes 1–10) into the
~300 kDa complex with an increased effi-
ciency in the fibroblast mitochondria of
affected individuals. In SURF1 fibroblast
mitochondria, [35S]PET100 was imported
(lanes 23–24) but not assembled into
the ~300 kDa complex (lanes 11–12) and
instead, assembled into a ~250 kDa com-
plex (**). [35S]PET100 additionally assem-
bled into a number of very high molecular
weight complexes in mitochondria of
affected individuals (*). Immunoblot
detection of SDHA, a complex II (CII) sub-
unit, was used as loading control.
(B) BN-PAGE and immunoblotting showed
that CIV holoenzyme was barely detect-
able in the fibroblasts of affected individ-
uals. The PET100 individuals also had CI/
CIII2 supercomplex and a small amount
of CI/CIII2/CIV supercomplex.
(C) Lentiviral-mediated overexpression of
wild-type PET100 restored COX2 levels
in the PET100 individuals but not the
SURF1 individuals (SURF1). Top: Bar graph
showing protein levels of COX2 relative to
VDAC1 (loading control) normalized to
control, before or after transduction. The
bars: mean of three biological replicates. Error bars: 5 1 standard error of the mean (SEM). *p < 0.001. Bottom: A representative blot
of SDS-PAGE immunoblot analysis of COX2 and VDAC1 from whole cell lysates before (-) and after (þ) transduction.
(D) Lentiviral-mediated overexpression of wild-type PET100 restored CIV assembly in the PET100 individuals but not in the SURF1
individual.PET100 Assembles into a 300 kDa Complex
Pet100p interactswith yeastCIV subunitsVII, VIIa, andVIII
(human COX7A, COX6C, and COX7C, respectively)68
whereas TAP-tagged PET100 interacts with COX7A2 in
HEK293 cells.67 BN-PAGE analysis showed that imported
PET100 assembles into a ~300 kDa complex that accumu-
lates over time and is dependent on the mitochondrial
membrane potential (Figure 3C). This complex is distinct
from the endogenous CIV (Figure 3C, lane 7). Its molecular
weight is higher than predicted from the known interac-
tions, implying that it contains additional subunits to those
listed above.
Mutant PET100 Does Not Form a Complex and Is Not
Imported into the Mitochondria
The c.3G>C mutation in PET100 was predicted to abolish
the initiation codon, which could potentially lead to
translation initiation at the nextmethionine located at res-
idue 10 (p.Met10) within the predicted transmembrane
domain67 (Figure 3D). This mutant protein (PET100D1-9)
was incapable of assembly into the ~300 kDa complex
(Figure 3C). Further analysis showed [35S]PET100D1-9 was
not imported into mitochondria (Figure 3C). Therefore,
we conclude that the N terminus of PET100 is essential
for its mitochondrial localization.The AmericThe Import and Assembly of [35S]PET100 into
Mitochondria of Affected Individuals
Because PET100D1-9 is not imported into mitochondria, it
is likely that mitochondria of PET100 individuals lack a
pre-existing ~300 kDa complex. To determine whether
[35S]PET100 is capable of de novo assembly, we imported
the full-length protein into mitochondria of PET100
individuals. An increased efficiency of complex assembly
and import was observed in cells from the PET100 indi-
viduals compared with cells from a healthy control or
SURF1 individual (Figure 4A). [35S]PET100 also assembled
into a number of very high molecular weight complexes
in the PET100 and SURF1 individuals (Figure 4A).
Interestingly, in the SURF1 individual, [35S]PET100
was imported but not assembled into the ~300 kDa
complex, instead assembling into a ~250 kDa complex
(Figure 4A). This suggests that PET100 interacts with
components that also rely on SURF1 for their biogenesis
(Figure 4A).
Mitochondria of PET100 Individuals Lacked CIV
Holoenzyme
Given the homology of PET100 to yeast Pet100p, we hy-
pothesized that individuals carrying mutant PET100
would harbor defects in CIV biogenesis. BN-PAGE analysisan Journal of Human Genetics 94, 209–222, February 6, 2014 217
Figure 5. Assembly of mtDNA-Encoded Subunits in D2
Mitochondria
(A) Assembly of newly synthesized mtDNA-encoded subunits into
OXPHOS complexes was studied by pulse/chase labeling with [35S]
methionine/cysteine in whole cells, followed by isolation of mito-
chondria and analysis by BN-PAGE and phosphorimaging. The
CIV holoenzyme was not assembled in D2mitochondria. The bot-
tom panel shows the steady-state levels of mature complexes IV
and I by immunoblotting. Abbreviations are as follows: CIVI, com-
plex IV subcomplex; CV, complex V.
(B) 2D-PAGE analysis of labeled mtDNA-encoded subunits from
D2 revealed a blocked entry of COX1, COX2, and COX3 into
the CIV holoenzyme, the stalling of these subunits in various
subcomplexes, and an increased turnover of COX2 and COX3.
The bottom panel shows the steady-state levels of mature
complexes IV and II by immunoblotting. The positions of
mtDNA-encoded CIV subunits COX1, COX2, and COX3 are
indicated.of fibroblasts from PET100 individuals revealed a
significant loss of CIV holoenzyme (Figure 4B). Affected
cells harbored a small amount of CI/CIII2/CIV super-
complex and a population of supercomplex lacking CIV
(CI/CIII2).218 The American Journal of Human Genetics 94, 209–222, FebruaryOverexpression of PET100 Restored COX2 Levels and
CIVAssembly in the Affected Lebanese Individuals
Lentiviral-mediated overexpression of PET100 in cultured
fibroblasts significantly increased COX2 levels (Figure 4C)
and restored CIV assembly (Figure 4D) in the affected
Lebanese individuals but not in the SURF1 individual.
This confirmed that the PET100 mutation caused the CIV
deficiency in the affected Lebanese individuals.Assembly of mtDNA-Encoded Subunits in Affected
Mitochondria
To investigate the consequences of PET100 loss, we
analyzed the assembly of newly synthesized mtDNA-en-
coded subunits into their respective OXPHOS complexes.
The mtDNA-encoded subunits efficiently assembled into
complexes I, III, and V in control and D2 fibroblasts.
However, almost no assembled CIV was detected in D2
(Figure 5A). We extended this analysis by using two-
dimensional (2D) BN-PAGE (Figure 5B). Before the chase,
COX2 and COX3 were present in an ~80 kDa subcomplex,
whereas COX1 was found in an ~100 kDa subcomplex
(CIVI), demonstrating their translation and entry into
the CIV assembly pathway in control and D2 mitochon-
dria (Figure 5B, 0 hr chase). In the control these subunits
were chased into mature CIV (Figure 5B, 3 and 24 hr
chase), but in D2 they remain stalled in various subcom-
plexes. COX2 and COX3 remain in their ~80 kDa subcom-
plex, whereas COX1 is stalled in the CIVI subcomplex and
an additional subcomplex slightly larger than mature CIV.
Interestingly, we observed significant turnover of COX2
and COX3 in D2 (Figure 5B, 24 hr chase), consistent
with the barely detectable level of COX2 in mitochondria
of PET100 individuals via immunoblotting.Discussion
CIV deficiency is one of themost common and best studied
OXPHOS disorders. A minority of molecularly diagnosed
affected individuals have mutations in CIV subunits, with
most having mutations in CIV biogenesis factors.5,6,15–18
Here we describe ten Australian affected individuals
from eight families with a homozygous PET100 mutation
causing CIV deficiency. Their clinical presentations were
similar to but distinct from SURF1 LS and all had Lebanese
ancestry. Half of the affected individuals died in infancy or
early childhood, and the others survived for periods up to
24 years or more. This variable survival could relate to the
effect of modifier genes or to the inherent variation in con-
ditions like LS, where acute life-threatening decompensa-
tions can be triggered by events such as intercurrent
illnesses. The affected individuals were shown to belong
to a single genetic complementation group by cell fusion
studies. Linkage and haplotype analyses identified a link-
age peak on chromosome 19 andMPS of the linkage region
prioritized PET100 as a top candidate gene. All ten affected
individuals were homozygous for a c.3G>C mutation6, 2014
predicted to abolish the first methionine residue. Ex-
pressing the wild-type and mutant PET100 proteins in
fibroblasts of affected individuals showed that only the
wild-type protein could rescue CIV assembly, providing
definitive proof of causation.
Similar to the recently described mitochondrial CIV
biogenesis factors COA5 and COX14,17,18 PET100 is a rela-
tively small protein (9.1 kDa). This small size meant that
PET100 was overlooked as a component of the mamma-
lian mitochondrial proteome, because previous proteomic
analyses of mouse mitochondria did not annotate most
proteins smaller than ~10 kDa.66 Knowledge of the mito-
chondrial proteome (MitoCarta proteins66) has been valu-
able in identifying other genes in which mutations cause
disease, because it allows filtering out of 95% of ‘‘nonmito-
chondrial’’ proteins fromwhole-exomedata sets.MitoCarta
was originally predicted to be more than 85% complete66
and thus is expected to miss a subset of mitochondrial pro-
teins. In this instance we identified PET100 as a result of
the combined power of detailed biochemical phenotyping,
complementation, linkage, and haplotype analyses on
multiple families, enabling highly effective filtering of
MPS variants.
The gene was originally termed C19orf79 before being
renamed earlier this year after its yeast ortholog, Pet100.
Identification of the distant homology between the
C19orf79/PET100 product and yeast Pet100p by Szklarczyk
and colleagues further enhanced the likelihood that
this was the correct candidate gene.67 Our discovery of a
PET100 mutation causing CIV deficiency demonstrates
its essential role in OXPHOS function. Nevertheless,
further investigation is required to elucidate its exact func-
tion. Its yeast homolog, Pet100p, is not required for the
synthesis and mitochondrial localization of CIV subunits
or the biogenesis of heme a and mitochondrial cyto-
chromes,68,71 and it is involved in a later step of CIVassem-
bly.68,70We showed that whereas themtDNA-encoded CIV
subunits in D2 mitochondria were translated, their assem-
bly into the mature CIV was impaired, leading to increased
turnover. Taken together, these results suggest that PET100
acts in the intermediate stage of CIV assembly, probably
coordinating the biogenesis of one or more nDNA-
encoded subunits.
To our knowledge this is only the second instance of
a founder mutation causing CIV deficiency. Mutations in
LRPPRC result in LS, French-Canadian type (LSFC [MIM
220111]), which is also known as Saguenay-Lac-Saint-
Jean CIV deficiency.20 All reported LRPPRC individuals
originated from the northern Que´bec region in Canada,
particularly the Saguenay-Lac-Saint-Jean region.72 Most
LRPPRC individuals are homozygous for a founder muta-
tion, c.1061C>T,72 which is estimated to have been intro-
duced into the French-Canadian population in the 17th
century from Europe.73 We estimated that the c.3G>C
PET100 mutation first occurred at least 520 years ago. The
parents of our PET100 individuals originated fromdifferent
regions in Lebanon and had different religious back-The Americgrounds, which is consistent with c.3G>C being a
relatively old mutation. To date, this mutation has been
identified only in individuals with a Lebanese ancestral
background and further studies are warranted into its
prevalence in Lebanon. Like individuals with SURF1 and
LRPPRCmutations, the clinical presentation of those with
PET100 mutations appears to be relatively homogeneous
and mutation analysis should be considered in individuals
with LS or Leigh-like encephalopathy and CIV deficiency.Supplemental Data
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